Drug Evaluation

The implementation of our CE-MS technology is possible from the very beginning of preclinical development (animal models) to the point of phase III or rather phase IV clinical trials. We are highly experienced in the efficient and time-saving assessment of newly developed as well as already existing pharmaceutical substances. Our approach in clinical proteomics enables the accurate clinical characterisation of patients and controls (high fidelity phenotyping). CE-MS profiling will accelerate drug development by ascertainment of statistically significant data from a small number of patients (defined cohorts) plus an enhancement in the determination of pharmaceutical drug safety.

Disease state specific polypeptide patterns obtained by our CE-MS technology help to select an appropriate therapy. Therapeutic effects of administered drug can be displayed and controlled in the polypetide patterns. This enables optimization of applied therapy (e.g. dosage modification).

Figure 1: CE-MS spectra from a patient with diabetic nephropathy before and after treatment with different daily doses (as indicated) of an angiotensin-receptor blocker. Mass/charge ratio is indicated on the left, migration time (in min) at the bottom, signal intensity is color-coded. Treatment resulted in a reduction of polypeptides indicative of diabetic nephropathy, consequently yielding a poorer match to the diabetic